Skip to main content

Year: 2024

Osisko Development Receives Environmental Management Act Permits for Cariboo Gold Project

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) is pleased to announce the granting of the Environmental Management Act permits for its 100%-owned Cariboo Gold Project (“Cariboo” or the “Project“) located in central British Columbia (“BC“), Canada. Together with the BC Mines Act permits secured on November 20, 2024, these approvals mark the successful completion of the permitting process for key approvals, solidifying the Cariboo Gold Project’s shovel-ready status. “We are very pleased with the receipt of the EMA permits, which, together with the Mines Act permits put the Cariboo Gold project in the enviable position of being construction and operation ready. This significant...

Continue reading

Lee Enterprises Reports Fourth Quarter and Full-Year FY24 results

Total Digital Revenue(1) was 51% of revenue in the quarter, representing $82MDigital-only subscription revenue increased 30%(2) in the quarterAmplified Digital® Agency revenue totaled $28M in the quarter, up 21% YOY(2), approaching $100M for the fiscal year DAVENPORT, Iowa, Dec. 12, 2024 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 73 markets, today reported preliminary fourth quarter fiscal 2024 financial results(3) for the period ended September 29, 2024. “The team achieved significant milestones in FY24, driving 41% revenue growth(2) in digital subscriptions and approaching $100 million in Amplified Digital® revenue for the fiscal year,” said Kevin Mowbray, Lee’s President...

Continue reading

The Lovesac Company Reports Third Quarter Fiscal 2025 Financial Results

Q3 FY25 Net Sales of $149.9 Million STAMFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World’s Most Adaptable Couch, today announced financial results for the third quarter of fiscal 2025, which ended November 3, 2024. Shawn Nelson, Chief Executive Officer, stated, “Near-term headwinds for our category clearly persisted through the pre-election period. However, we gained market share and strengthened our competitive position through our relentless focus on product innovation and operational excellence. Our expanding portfolio of innovative products is resonating with customers and creating new avenues for sustained growth in the future. The soft launch of our Reclining Seat in the fourth quarter is...

Continue reading

InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025

MIAMI, Dec. 12, 2024 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition. Marvin Slosman, Chief Executive Officer of InspireMD, commented, “Craig has served the company for 15 years with a tireless commitment to building our business as a global leader in carotid interventions. As we advance our priorities, including potential U.S. FDA approval in the first half of 2025, along with a heightened focus on the investment community, Craig made this decision confident in the future...

Continue reading

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 11 12 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Public Transportation Market Size to Reach USD 652.37 Billion by 2031 | SkyQuest Technology

Westford, USA, Dec. 12, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global Public Transportation Market Share will reach a value of USD 652.37 Billion by 2031, with a CAGR of 12.90% during the forecast period (2024-2031). Expansion in the public transportation industry is significantly driven by several reasons, including higher demand for government initiatives aiming to reduce traffic congestion among public. Many governments from across the globe are planning their intentions to increase the locality-based use of public transportation. So, the government through focusing on the deployment of technology, innovative finance, institutional arrangements, and even better experience of the user itself intends to promote more utility of public transport. Download a detailed overview: https://www.skyquestt.com/sample-request/public-transportation-market...

Continue reading

Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia

Avatrombopag PDUFA date set for July 24, 2025 WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) — Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for avatrombopag (DOPTELET®) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 24, 2025. The FDA also accepted Sobi’s New Drug Application (NDA) for avatrombopag for oral suspension. Avatrombopag for oral suspension is a capsule where its granules are sprinkled onto a soft food or liquid to prepare for...

Continue reading

Form 8.3 – [ECKOH PLC – 11 12 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ECKOH PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Liquidity Services Announces Fourth Quarter Fiscal Year 2024 Financial Results

Record GMV and Market Share Expansion Cap Year of Innovation and Excellence BETHESDA, Md., Dec. 12, 2024 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ:LQDT; www.liquidityservices.com), a leading global commerce company powering the circular economy, today announced its financial results for the quarter ended September 30, 2024, as compared to the corresponding prior year quarter:Gross Merchandise Volume (GMV) of $361.0 million, up 14%, and Revenue of $106.9 million, up 34% GAAP Net Income of $6.4 million, up $0.1 million, and GAAP Diluted Earnings Per Share (EPS) of $0.20 Non-GAAP Adjusted EBITDA of $14.5 million, up 13%, and Non-GAAP Adjusted EPS of $0.32, up 23% Cash balances of $155.5 million1 with zero financial debt“Our strong fourth quarter results capped a successful year of market share expansion and consistent...

Continue reading

Form 8.5 (EPT/RI) – Warpaint London Plc

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Shore Capital Stockbrokers Ltd(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Warpaint London Plc(c)        Name of the party to the offer with which exempt principal trader is connected: Warpaint London Plc(d)        Date dealing undertaken: 11 December 2024(e)        Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? Yes – Brand Architekts Group plc2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER (a)        Purchases...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.